GO:0032813 tumor necrosis factor receptor superfamily binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032813 tumor necrosis factor receptor superfamily binding is a molecular function describing the selective binding of a protein to a member of the tumor necrosis factor receptor (TNFR) superfamily.
• TNFR superfamily binding is the first step in TNFR signaling and determines which ligands activate which receptors, shaping outcomes such as immune activation, cell survival, or apoptosis.
• The interaction is structurally encoded by a conserved TNF homology domain in ligands and cysteine-rich domains in receptors, giving the system its specificity and oligomeric signaling behavior.
• Dysregulated TNFR superfamily binding underlies inflammatory and autoimmune diseases, including inflammatory bowel disease and Crohn's disease, through ligands such as TL1A and their receptors.
• The function can be studied with binding assays, structural biology, CRISPR knockout/knock-in models, and computational design of antagonists or agonists.
• EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening to dissect TNFR superfamily binding in disease-relevant contexts.
Description
GO:0032813 tumor necrosis factor receptor superfamily binding is a molecular function that describes the binding of a protein to a member of the tumor necrosis factor receptor (TNFR) superfamily. This function is central to the TNF/TNFR signaling axis, a major communication system that controls inflammation, immune cell activation, proliferation, and cell death. Because TNFR superfamily binding determines which ligand engages which receptor, it is a key determinant of signaling specificity and biological outcome. Researchers study this function to understand how immune responses are initiated and how they go wrong in disease. The TNFR superfamily includes receptors such as TNFRSF1A, TNFRSF1B, FAS, and death receptor 3 (DR3), and ligands such as TNF, TL1A, and FasL. The binding event itself is a protein-protein interaction, but its consequences are broad: it nucleates receptor oligomerization and assembly of post-receptor signaling complexes. Structural studies have shown that TNF family ligands and receptors use conserved folds and oligomeric architectures to achieve high specificity and tunable signaling. In translational research, this function is a target for biologic drugs and for computational design of antagonists and agonists. Inflammatory bowel disease and Crohn's disease are prominent examples where TL1A/DR3 binding contributes to pathogenic T cell responses. This article summarizes the definition, mechanism, key genes, disease links, and experimental methods for studying GO:0032813, with a focus on how CRISPR models can be used to test causality.
tumor necrosis factor receptor superfamily binding At A Glance
| GO ID | GO:0032813 |
|---|---|
| GO term | tumor necrosis factor receptor superfamily binding |
| Ontology | molecular_function |
| Synonym | TNF receptor superfamily binding |
| Major function | Binding to a member of the tumor necrosis factor receptor superfamily, initiating receptor clustering and downstream signaling |
| Structural basis | Conserved TNF homology domains in ligands and cysteine-rich domains in receptors mediate specificity |
| Signaling consequence | Assembly of post-receptor signaling complexes that control inflammation, survival, and cell death |
| Disease relevance | Inflammatory and autoimmune diseases, including inflammatory bowel disease and Crohn's disease |
| Therapeutic relevance | Target for antagonists and agonists designed to modulate TNFR superfamily signaling |
What Is GO:0032813?
In the Gene Ontology, GO:0032813 tumor necrosis factor receptor superfamily binding is defined as binding to a member of the tumor necrosis factor receptor superfamily. In practical terms, it is the molecular interaction between a protein (typically a TNF superfamily ligand or a receptor-binding protein) and a TNFR superfamily receptor. This function is a molecular_function term, meaning it describes what a protein does at the molecular level rather than a whole pathway or cellular location. The synonym TNF receptor superfamily binding is used interchangeably. The function is mediated by structured protein-protein interfaces, often involving conserved TNF homology domains in ligands and cysteine-rich domains in receptors. Binding can be homotypic or heterotypic and can lead to receptor clustering, which is required for downstream signaling complex assembly.
Why Is tumor necrosis factor receptor superfamily binding Important in Cell Biology?
GO:0032813 tumor necrosis factor receptor superfamily binding is important because it is the molecular gatekeeper of TNFR superfamily signaling, a system that controls fundamental immune and tissue decisions such as inflammation, proliferation, survival, and apoptosis. The specificity of this binding determines which ligand-receptor pairs are engaged, and therefore whether a cell receives a survival or death signal. Because dysregulated TNFR superfamily binding is linked to autoimmune and inflammatory diseases, it is a major target for therapeutic intervention. Understanding this function at the structural and cellular level enables rational design of biologics and small molecules that block or mimic binding. In research, it provides a defined molecular endpoint for CRISPR screens and functional assays.
• Defines ligand-receptor specificity in the TNF/TNFR superfamily, a central immune signaling system.
• Controls assembly of post-receptor signaling complexes that determine cell fate.
• Contributes to inflammatory and autoimmune disease pathogenesis, including inflammatory bowel disease.
• Is implicated in pathogenic T helper cell generation in Crohn's disease via TL1A/DR3 binding.
• Provides a structural template for designing TNFR superfamily antagonists and agonists.
• Serves as a molecular function annotation for interpreting genome-wide CRISPR screens.
• Enables mechanistic dissection of cytokine-receptor interactions in immune cells.
• Supports biomarker and drug target discovery in chronic inflammation.
• Can be modeled with knockout, knock-in, and overexpression cell systems for causality testing.
• Links structural biology to functional immunology through conserved binding interfaces.
Molecular Mechanism of tumor necrosis factor receptor superfamily binding
Ligand recognition and receptor engagement
In simple terms: A TNF-family ligand finds and binds its specific receptor on the cell surface.
The binding function begins with recognition between a TNF superfamily ligand and a TNFR superfamily receptor. Ligands typically present a conserved TNF homology domain that forms a compact trimer, while receptors contain cysteine-rich domains that create the binding interface. This interaction is highly specific, ensuring that ligands such as TNF or TL1A engage only their cognate receptors. Structural studies have defined the principles of this recognition, including the role of oligomeric assembly in stabilizing the complex.
Receptor clustering and signaling complex assembly
In simple terms: Once bound, receptors group together and recruit signaling proteins inside the cell.
Binding of a ligand to a TNFR superfamily receptor promotes receptor clustering, which is required for efficient signal transduction. The clustered receptors then nucleate assembly of post-receptor signaling complexes, often through intracellular death domains or TRAF-binding motifs. This step converts the extracellular binding event into an intracellular signal, determining whether the cell activates NF-kB, MAPK, or death pathways. The stoichiometry and geometry of the ligand-receptor complex influence the strength and duration of signaling.
Structural determinants of binding specificity
In simple terms: The shape and chemical properties of the ligand and receptor surfaces decide which pairs can bind.
The specificity of GO:0032813 is encoded in the three-dimensional structures of the interacting partners. TNF family ligands share a jelly-roll fold that presents conserved receptor-binding sites, while TNFR superfamily receptors use repeated cysteine-rich domains to form elongated binding surfaces. Variations in these interfaces allow the superfamily to achieve selective binding despite shared folds. Computational and structural studies have leveraged these principles to design potent antagonists and agonists.
Regulation of binding availability and affinity
In simple terms: Cells control when and how strongly binding happens by changing receptor levels and shedding soluble decoys.
The binding function is regulated at multiple levels, including receptor expression, ligand availability, and shedding of soluble receptors or decoys. For example, soluble forms of TNFR superfamily members can compete with membrane receptors for ligand, modulating signaling output. Post-translational modifications and local membrane environment can also influence binding affinity and clustering. These regulatory layers ensure that TNFR superfamily binding is context-dependent and tightly controlled.
Functional consequences of binding
In simple terms: The binding event ultimately tells the cell to survive, proliferate, or die.
Downstream of binding, TNFR superfamily signaling can activate NF-kB and MAPK pathways to promote survival and inflammation, or caspase-dependent death pathways to induce apoptosis. The outcome depends on the specific ligand-receptor pair and cellular context. In immune cells, this binding can drive differentiation programs, such as pathogenic T helper 9 cell generation in Crohn's disease. Thus, GO:0032813 is a molecular decision point with broad physiological and pathological consequences.
Key Genes Involved in GO:0032813 tumor necrosis factor receptor superfamily binding
The following genes and proteins are central to tumor necrosis factor receptor superfamily binding, either as ligands, receptors, or signaling adaptors that mediate the function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNF | Prototype TNF superfamily ligand that binds TNFRSF1A/TNFRSF1B | Model ligand for studying TNFR superfamily binding and inflammation |
| TNFRSF1A | Receptor for TNF; mediates inflammatory and survival signaling | Key receptor for binding assays and knockout studies |
| TNFRSF1B | Receptor for TNF; modulates immune and endothelial responses | Target for differential binding studies |
| FAS | Death receptor that binds FASLG and triggers apoptosis | Model for binding-induced cell death |
| FASLG | Ligand for FAS; induces receptor clustering and apoptosis | Used to study binding specificity and signaling outcomes |
| TNFSF15 (TL1A) | Ligand that binds DR3/TNFRSF25 | Central to inflammatory bowel disease and Crohn's disease research |
| TNFRSF25 (DR3) | Receptor for TL1A; activates T cell responses | Target for autoimmune and IBD models |
| TRAF2 | Adaptor recruited to TNFR superfamily signaling complexes | Mediates post-receptor signaling after binding |
| TRAF5 | Adaptor involved in TNFR superfamily signaling | Studied for complex assembly and NF-kB activation |
| TRADD | Adaptor that links TNFR1 to downstream pathways | Key for understanding binding-to-signaling coupling |
| RIPK1 | Kinase recruited to TNFR1 complex; regulates survival/death | Model for post-binding fate decisions |
| NFKB1 | Transcription factor activated downstream of TNFR binding | Readout of TNFR superfamily signaling |
| CASP8 | Initiator caspase in death receptor signaling | Measures apoptotic outcome of binding |
| LTB | Ligand for LTBR; involved in lymphoid tissue organization | Studied in TNFR superfamily binding context |
| LTBR | Receptor for lymphotoxin; activates NF-kB | Model for non-death TNFR signaling |
| EDA | Ligand for EDAR; involved in ectodermal development | Example of developmental TNFR superfamily binding |
| EDAR | Receptor for EDA; activates NF-kB in development | Used to study binding in developmental contexts |
How Is tumor necrosis factor receptor superfamily binding Regulated?
The availability and outcome of tumor necrosis factor receptor superfamily binding are regulated at several levels. Receptor expression levels and ligand production determine whether binding can occur, while soluble decoy receptors and shedding can sequester ligands and dampen signaling. Post-receptor complex assembly is controlled by adaptor proteins such as TRADD, TRAF2, and RIPK1, which influence whether binding leads to NF-kB activation or cell death. Structural features of the ligand-receptor interface also regulate binding affinity and specificity, as reviewed in structural studies of the TNF superfamily. In disease contexts, chronic overexpression of ligands such as TL1A can sustain binding and drive pathogenic T cell responses. Computational design approaches have further shown that binding can be tuned with engineered antagonists or agonists.
tumor necrosis factor receptor superfamily binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFSF15 (TL1A) | Inflammatory bowel disease and Crohn's disease | Knockout and overexpression intestinal epithelial or T cell models |
| TNFRSF25 (DR3) | Autoimmune inflammation and T helper 9 responses | Knockout T cell models and point-mutation binding studies |
| TNF | Chronic inflammatory diseases | Knockout and knock-in models for binding specificity |
| FAS | Apoptosis-related immune disorders | Point-mutation and knockout cell lines for death signaling |
| TNFRSF1A | Inflammatory signaling and tissue damage | Overexpression and knockout models for pathway dissection |
Inflammatory bowel disease and Crohn's disease
Dysregulated tumor necrosis factor receptor superfamily binding contributes to inflammatory bowel disease pathogenesis, particularly through the TL1A/DR3 axis. TL1A binding to DR3 promotes pathogenic T helper 9 cell generation in experimental Crohn's disease, linking the molecular function to disease severity. These findings support targeting TNFR superfamily binding as a therapeutic strategy in chronic intestinal inflammation.
Autoimmune and inflammatory diseases
Beyond the gut, TNFR superfamily binding is implicated in a range of inflammatory and autoimmune conditions where excessive ligand-receptor engagement drives tissue damage. The TL1A/DR3 pathway has been reviewed as a contributor to multiple autoimmune diseases, highlighting the broad relevance of GO:0032813. Because binding specificity determines which pathways are activated, it is a focal point for drug discovery.
Cell death and apoptosis disorders
Binding of death ligands such as FASLG to FAS triggers receptor clustering and apoptotic signaling, a process relevant to disorders of immune homeostasis. Structural principles of TNF superfamily signaling explain how binding can switch between survival and death outcomes. This makes GO:0032813 relevant to diseases involving defective or excessive apoptosis.
From tumor necrosis factor receptor superfamily binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate ligand bind a specific TNFR superfamily receptor? | Knockout of the receptor followed by ligand binding assay |
| Which residues mediate binding specificity? | Point-mutation knock-in of ligand or receptor interface residues |
| Does binding drive pathogenic T cell differentiation? | Knock-in or knockout T cell models with TL1A/DR3 |
| Can binding be blocked therapeutically? | Overexpression of ligand plus antagonist treatment in cell models |
| What signaling complexes assemble after binding? | Tagged knock-in of adaptors such as TRAF2 or TRADD |
| Which genes regulate TNFR superfamily binding outcomes? | CRISPR library screening in immune cell lines |
How to Study the tumor necrosis factor receptor superfamily binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Ligand-receptor interaction validation |
| ELISA-based binding assay | Specific binding between ligand and receptor | Screening blocking antibodies |
| Flow cytometry | Cell surface binding and receptor occupancy | Immune cell binding studies |
| Cryo-EM / crystallography | Three-dimensional structure of complexes | Mapping binding interfaces |
| Computational design | Predicted binders and affinity optimization | Generating antagonists/agonists |
| CRISPR knockout screen | Genes required for binding or signaling | Functional genomics of TNFR superfamily |
| Reporter assay | NF-kB or apoptosis pathway activation | Post-binding signaling readout |
| Live-cell imaging | Receptor clustering and complex assembly | Spatiotemporal analysis of binding |
Binding assays and surface plasmon resonance
Direct measurement of tumor necrosis factor receptor superfamily binding can be performed using surface plasmon resonance, ELISA-based binding assays, or flow cytometry with labeled ligands. These methods quantify affinity and specificity between ligand and receptor ectodomains. They are typically used to validate predicted interactions and to screen for blocking antibodies or designed antagonists.
Structural biology and computational design
X-ray crystallography, cryo-EM, and computational modeling reveal the structural basis of TNFR superfamily binding. Target-conditioned diffusion has been used to generate potent TNFR superfamily antagonists and agonists, demonstrating how structural knowledge enables design. These approaches are applied to map binding interfaces and engineer improved binders.
CRISPR functional genomics
CRISPR knockout and knock-in screens can identify genes that regulate TNFR superfamily binding and downstream signaling. Pooled library screening coupled with binding readouts or reporter assays enables unbiased discovery of modulators. These methods are used to link genotype to binding phenotype in immune and inflammatory models.
Cell-based signaling and imaging
Reporter assays, phospho-flow, and live-cell imaging measure signaling outcomes after binding, such as NF-kB activation or caspase cleavage. Imaging can visualize receptor clustering and complex assembly at the single-cell level. These methods are applied to test how binding strength and duration affect cell fate.
How CRISPR Can Be Used to Study GO:0032813 tumor necrosis factor receptor superfamily binding
Knockout
CRISPR knockout of TNFR superfamily receptors or ligands can abolish specific binding events, providing a clean background to test whether a candidate interaction is required for a phenotype. Knockout models are widely used to validate ligand-receptor pairs and to dissect downstream signaling.
Point Mutation
Point mutations at ligand or receptor binding interfaces can selectively disrupt or enhance binding without deleting the entire protein. These models are valuable for testing which residues determine specificity and for separating binding from other functions.
Knock-in
Knock-in of tagged or disease-associated variants allows tracking of receptor complexes and analysis of binding in a physiological context. Knock-in models can also introduce humanized binding domains to study species-specific interactions.
Overexpression
Overexpression of ligands or receptors can amplify binding signals and reveal dose-dependent effects on inflammation or cell death. These models are useful for screening antagonists and for modeling chronic inflammatory states.
How EDITGENE Supports tumor necrosis factor receptor superfamily binding Research
Researchers studying tumor necrosis factor receptor superfamily binding-related genes often need to determine whether a candidate gene is causally involved in ligand-receptor engagement, signaling output, or disease phenotypes. EDITGENE provides the CRISPR cell models and screening services needed to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for tumor necrosis factor receptor superfamily binding research.
Frequently Asked Questions About tumor necrosis factor receptor superfamily binding
What is GO:0032813 tumor necrosis factor receptor superfamily binding?
GO:0032813 is a Gene Ontology molecular function term defined as binding to a member of the tumor necrosis factor receptor superfamily.
What genes are involved in tumor necrosis factor receptor superfamily binding?
Key genes include TNF, TNFRSF1A, TNFRSF1B, FAS, FASLG, TNFSF15 (TL1A), TNFRSF25 (DR3), and adaptors such as TRAF2 and TRADD.
Why is TNFR superfamily binding important in immunology?
It determines which ligand-receptor pairs are engaged and controls downstream inflammation, survival, and cell death signaling.
How is tumor necrosis factor receptor superfamily binding studied?
It is studied with binding assays, structural biology, CRISPR screens, and cell-based signaling assays.
What diseases are linked to TNFR superfamily binding?
Inflammatory bowel disease, Crohn's disease, and other autoimmune and inflammatory conditions are linked to dysregulated TNFR superfamily binding.
What is the role of TL1A and DR3 in TNFR superfamily binding?
TL1A binds DR3 to activate T cell responses, and this interaction contributes to pathogenic T helper 9 cell generation in Crohn's disease.
Can CRISPR be used to study TNFR superfamily binding?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can test causality and dissect binding mechanisms.
What is the structural basis of TNFR superfamily binding?
Conserved TNF homology domains in ligands and cysteine-rich domains in receptors mediate specific binding and oligomerization.
How can TNFR superfamily binding be blocked therapeutically?
Engineered antagonists and antibodies that interfere with ligand-receptor binding are being developed and tested.
What services does EDITGENE offer for TNFR superfamily binding research?
EDITGENE offers knockout, point-mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
GO:0032813 tumor necrosis factor receptor superfamily binding is a fundamental molecular function that governs ligand-receptor specificity in the TNF/TNFR superfamily and shapes immune and inflammatory outcomes. Its structural basis is well defined, and its dysregulation is linked to diseases such as inflammatory bowel disease and Crohn's disease. Studying this function with binding assays, structural biology, and CRISPR models provides a path to new therapeutics. EDITGENE supports this research with customizable cell models and screening services.
References
- 1. Idriss HT et al.. 2000. TNF alpha and the TNF receptor superfamily: structure-function relationship(s).. Microsc Res Tech 50(3):184-95 PMID: 10891884
- 2. Xu WD et al.. 2022. Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review.. Front Immunol 13:891328 PMID: 35911746
- 3. Menghini P et al.. 2025. Tumor Necrosis Factor-Like Ligand 1A/Death Receptor 3 Signaling Regulates the Generation of Pathogenic T Helper 9 Cells in Experimental Crohn's Disease.. Gastroenterology 169(5):892-908 PMID: 40204100
- 4. Glögl M et al.. 2024. Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists.. Science 386(6726):1154-1161 PMID: 39636970
- 5. Meng F et al.. 2023. Tumor necrosis factor-like cytokine 1A plays a role in inflammatory bowel disease pathogenesis.. Proc Natl Acad Sci U S A 120(34):e2120771120 PMID: 37579137
- 6. Wu H. 2004. Assembly of post-receptor signaling complexes for the tumor necrosis factor receptor superfamily.. Adv Protein Chem 68:225-79 PMID: 15500863
- 7. Vanamee ÉS et al.. 2018. Structural principles of tumor necrosis factor superfamily signaling.. Sci Signal 11(511) PMID: 29295955
- 8. Zhang G. 2004. Tumor necrosis factor family ligand-receptor binding.. Curr Opin Struct Biol 14(2):154-60 PMID: 15093829
